MAIA Biotechnology’s THIO shows positive survival data in lung cancer study

MAIA Biotechnology announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer – NSCLC -. A Phase 2 clinical trial, THIO-101, is evaluating THIO sequenced with Regeneron’s immune checkpoint inhibitor cemiplimab – Libtayo- in patients with advanced NSCLC who failed two or more standard-of-care therapy regimens. Published available results suggest that overall survival in third-line patients is 5.8 months. As of August 01, 2024, 16 patients had survival follow-up surpassing 12 months, including 9 in third line treatment. Interim median survival follow-up in 3L was 10.6 months. The 12-month survival data corresponds to the company’s most recent data from THIO-101 demonstrating favorable disease control and overall response rates. In April, THIO 180mg + CPI in third-line treatment showed, in part, overall response rate of 38%, disease control rate of 88% and median progression-free survival of 5.5 months. MAIA expects to release full efficacy results of THIO-101 this year.